Abstract:Cellular senescence is implicated in ageing and associated with a broad spectrum of age-related diseases. Importantly, a cell can initiate the senescence program irrespective of the organism's age. Various stress signals, including those defined as ageing hallmarks and alterations leading to cancer development, oncogene activation, or loss of cancer-suppressive functions, can trigger cellular senescence. The primary outcome of these alterations is the activation of nuclear factor (NF)-κB, thereby inducing the senescence-associated secretory phenotype (SASP). Proinflammatory cytokines and chemokines, components of this phenotype, contribute to chronic systemic sterile inflammation, commonly referred to as inflamm-ageing. This inflammation is linked to age-related diseases (ARDs), frailty, and increased mortality in older individuals. Additionally, senescent cells (SCs) accumulate in multiple tissues with age and are believed to underlie the organism functional decline, as demonstrated by models. An escalating effort has been dedicated to identify senotherapeutics that selectively target SCs by inducing apoptosis; these drugs are termed senolytics. Concurrently, small molecules that suppress senescent phenotypes without causing cell death are known as senomorphics. Both natural and synthetic senotherapeutics, along with immunotherapies employing immune cell-mediated clearance of SCs, currently represent the most promising strategies to combat ageing and ARDs. Indeed, it is fascinating to observe that information regarding the immune reaction to SCs indicates that regulation by specific lymphocyte subsets, elevated in the oldest centenarians, plays a role in attaining extreme longevity. Regardless, the application of methods already utilized in cancer treatment, such as CAR cells and monoclonal antibodies, broadens the spectrum of potential approaches to be utilized.

Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development

Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies

Autophagy Facilitates Age-Related Cell Apoptosis—a New Insight from Senile Cataract

Insights into targeting cellular senescence with senolytic therapy: The journey from preclinical trials to clinical practice

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Emerging senolytic agents derived from natural products

Targeting Senescent Cells and Tumor Therapy (Review)

Therapeutic strategies targeting cellular senescence for cancer and other diseases

Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart

Cellular Senescence: Mechanisms and Therapeutic Potential

Senotherapeutics to Counteract Senescent Cells Are Prominent Topics in the Context of Anti-Ageing Strategies

Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria

Exploiting senescence for the treatment of cancer

Advances in Nanotherapy for Targeting Senescent Cells

Senescence as a therapeutic target in cancer and age-related diseases

Subcellular structure, heterogeneity, and plasticity of senescent cells

Cellular senescence and senolytics: the path to the clinic

Cellular senescence: the good, the bad and the unknown

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Cellular Senescence and Senolytic Agents: Recent Updates on Their Role and Applications